July 23 Biogen Idec Inc reported
sharply higher-than-expected quarterly revenue on surging sales
of its new Tecfidera oral treatment for multiple sclerosis, and
the company raised its full-year profit forecast.
The company on Wednesday said it had earned $723.1 million,
or $3.01 per share, in the second quarter. That compared with
$491 million, or $2.06 per share, a year earlier, when it took a
legal settlement charge.
Global revenue rose 40 percent to $2.42 billion, well above
the average forecast of $2.16 billion among analysts surveyed by
Thomson Reuters I/B/E/S.
(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)